Association of the metabolic dysfunction-associated steatotic liver disease with cardiovascular and kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study

IF 7.4 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2025-09-28 DOI:10.1016/j.diabres.2025.112927

Huihui Ren , Mengyuan Hu , Yongli Yan , Mengke Cheng , Chengru Yang , Gang Yuan , Tingting Du

{"title":"Association of the metabolic dysfunction-associated steatotic liver disease with cardiovascular and kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study","authors":"Huihui Ren , Mengyuan Hu , Yongli Yan , Mengke Cheng , Chengru Yang , Gang Yuan , Tingting Du","doi":"10.1016/j.diabres.2025.112927","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>This study explored the link between liver fibrosis and left ventricular hypertrophy (LVH), a good indicator of cardiovascular disease (CVD), and chronic kidney disease (CKD) risk in type 2 diabetes mellitus (T2DM) patients.</div></div><div><h3>Methods</h3><div>We analyzed data from 2,436 T2DM patients who visited our clinic between 2022 and 2024. Liver fibrosis was evaluated using NAFLD Fibrosis Score (NFS). We applied logistic regression to assess the relationship between liver fibrosis and LVH/CKD risk.</div></div><div><h3>Results</h3><div>Among the 2,436 participants (63.79 % male, mean [SD] age 53.08 [12.65] years), the prevalence of LVH, and CKD was 38.88 %, and 34.69 %. Individuals with NFS-defined advanced fibrosis had significantly higher risks of LVH (OR 1.45, 95 % CI [1.16–1.81]) and CKD (OR 1.94, 95 % CI [1.56–2.41]), after adjusting for established cardiovascular risk markers. Results remained consistent regardless of body mass index (BMI), or lipid profile status. We also observed that worsening liver fibrosis was associated with a higher stage of cardiovascular-kidney-metabolic (CKM) syndrome.</div></div><div><h3>Conclusions</h3><div>Liver fibrosis is independently associated with increased LVH/CKD risk and CKM stage in T2DM patients. These findings indicate that metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive stage (liver fibrosis) should be introduced into the CKM staging structure to enhance risk stratification.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112927"},"PeriodicalIF":7.4000,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822725009416","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This study explored the link between liver fibrosis and left ventricular hypertrophy (LVH), a good indicator of cardiovascular disease (CVD), and chronic kidney disease (CKD) risk in type 2 diabetes mellitus (T2DM) patients.

Methods

We analyzed data from 2,436 T2DM patients who visited our clinic between 2022 and 2024. Liver fibrosis was evaluated using NAFLD Fibrosis Score (NFS). We applied logistic regression to assess the relationship between liver fibrosis and LVH/CKD risk.

Results

Among the 2,436 participants (63.79 % male, mean [SD] age 53.08 [12.65] years), the prevalence of LVH, and CKD was 38.88 %, and 34.69 %. Individuals with NFS-defined advanced fibrosis had significantly higher risks of LVH (OR 1.45, 95 % CI [1.16–1.81]) and CKD (OR 1.94, 95 % CI [1.56–2.41]), after adjusting for established cardiovascular risk markers. Results remained consistent regardless of body mass index (BMI), or lipid profile status. We also observed that worsening liver fibrosis was associated with a higher stage of cardiovascular-kidney-metabolic (CKM) syndrome.

Conclusions

Liver fibrosis is independently associated with increased LVH/CKD risk and CKM stage in T2DM patients. These findings indicate that metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive stage (liver fibrosis) should be introduced into the CKM staging structure to enhance risk stratification.

查看原文本刊更多论文

2型糖尿病患者代谢功能障碍相关脂肪变性肝病与心血管和肾脏疾病的相关性：一项横断面研究

目的：本研究探讨肝纤维化与左心室肥厚（LVH）之间的关系，LVH是2型糖尿病（T2DM）患者心血管疾病（CVD）和慢性肾脏疾病（CKD）风险的良好指标。方法：我们分析了2022年至2024年间就诊的2436例T2DM患者的数据。采用NAFLD纤维化评分（NFS）评估肝纤维化。我们应用逻辑回归来评估肝纤维化与LVH/CKD风险之间的关系。结果：2436例患者中，男性63.79%，平均[SD]年龄53.08[12.65]岁，LVH患病率为38.88%，CKD患病率为34.69%。在调整了已建立的心血管风险指标后，患有nfs定义的晚期纤维化的个体发生LVH （OR 1.45, 95% CI[1.16-1.81]）和CKD （OR 1.94, 95% CI[1.56-2.41]）的风险明显更高。无论身体质量指数（BMI）或血脂状况如何，结果都是一致的。我们还观察到肝纤维化的恶化与心血管-肾脏代谢（CKM）综合征的较高阶段相关。结论：肝纤维化与T2DM患者LVH/CKD风险增加和CKM分期独立相关。这些发现表明，代谢功能障碍相关的脂肪变性肝病（MASLD）及其进展阶段（肝纤维化）应纳入CKM分期结构，以加强风险分层。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.